» Articles » PMID: 37592029

The Exit of Nanoparticles from Solid Tumours

Overview
Journal Nat Mater
Date 2023 Aug 17
PMID 37592029
Authors
Affiliations
Soon will be listed here.
Abstract

Nanoparticles enter tumours through endothelial cells, gaps or other mechanisms, but how they exit is unclear. The current paradigm states that collapsed tumour lymphatic vessels impair the exit of nanoparticles and lead to enhanced retention. Here we show that nanoparticles exit the tumour through the lymphatic vessels within or surrounding the tumour. The dominant lymphatic exit mechanism depends on the nanoparticle size. Nanoparticles that exit the tumour through the lymphatics are returned to the blood system, allowing them to recirculate and interact with the tumour in another pass. Our results enable us to define a mechanism of nanoparticle delivery to solid tumours alternative to the enhanced permeability and retention effect. We call this mechanism the active transport and retention principle. This delivery principle provides a new framework to engineer nanomedicines for cancer treatment and detection.

Citing Articles

Enhancing immunotherapy with tumour-responsive nanomaterials.

Linderman S, DeRidder L, Sanjurjo L, Foote M, Alonso M, Kirtane A Nat Rev Clin Oncol. 2025; .

PMID: 40050505 DOI: 10.1038/s41571-025-01000-6.


A multistage drug delivery approach for colorectal primary tumors and lymph node metastases.

Yuan Y, Lin Q, Feng H, Zhang Y, Lai X, Zhu M Nat Commun. 2025; 16(1):1439.

PMID: 39920155 PMC: 11806101. DOI: 10.1038/s41467-025-56768-z.


Multivalent ionizable lipid-polypeptides for tumor-confined mRNA transfection.

Zhao X, Zhang Y, Wang X, Fu Z, Zhong Z, Deng C Bioact Mater. 2025; 46():423-433.

PMID: 39850023 PMC: 11754973. DOI: 10.1016/j.bioactmat.2024.12.032.


Nanoparticle innovations in targeted cancer therapy: advancements in antibody-drug conjugates.

Abdelhamid M, Wadan A, Saad H, El-Dakroury W, Hageen A, Mohammed D Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39825965 DOI: 10.1007/s00210-024-03764-7.


Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells.

Abdessalem M, Adham S Oncol Res. 2024; 33(1):27-44.

PMID: 39735681 PMC: 11671623. DOI: 10.32604/or.2024.056955.